InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$300.15

2026-10-16

Market Cap

$14.5B

Volume

0.7M

52-Wk High

$333.30

52-Wk Low

$146.20

Trailing PE

-62.0

P/S

3.62

Gross Margin

32.2%

Net Margin

-6.0%

ROE

-8%

ROIC

8%

Piotroski

5/9

Altman Z

2.7

1-Yr Return

+71.6%

5-Yr Return

+132.0%

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

SectorHealthcareIndustryMedical - Diagnostics & ResearchExchangeNYSEMarket Cap$14.5BEmployees19,700 (SEC-filed)CEOBirgit GirshickIPO2000-06-23CountryUS

251 Ballardvale Street, Wilmington, MA 01887 · Tel 781 222 6000 · criver.com

INSIDERSTREET SCORE27 / 100Street mean $315.00 (17 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALTWO-WAY FLOW$0.0M buys against $42.9M sells / 6 mo

1 Year vs S&P 500 · CRL +71.6% · S&P 500 +15.9% · spread +55.8pp

7 Years vs S&P 500 · CRL +132.0% · S&P 500 +189.9% · spread -57.9pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE27of 100

Score Breakdown

Profitability	18/100
Growth	32/100
Momentum	35/100
Quality	41/100
Earnings Quality	43/100
Balance Sheet	31/100
Value	28/100
Risk (safety)	50/100
Overall	27.0/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
ICLR	46
RVTY	50
MEDP	84
EXAS	50
GH	42
QGEN	66
CRL	27

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 57 in 23 Q3, latest 27 — -30 since. Dropped below the 40 line in 24 Q4, at 39. Fell in 3 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY27 / 100IS Score 27.0 / 100 · -30.0 from peak of 57

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 71 / 100 · Power +42 · 17 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 27, price structure 71 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 27.0	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 32 → 31 → 17 → 27	the direction matters more than the level
Technical vote share back above 50%	now 82%	price structure no longer broken
Institutional holder count rises two quarters running	peak 678 → now 573	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)0 buysnone disclosed

Insider Buys (180d)1none disclosed

ETF Funds (30d)552 up / 513 downnet +39 funds

Institutions Added (13F)14managers opening or increasing

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 678 · latest 573 (-105 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	573	57.3M	$12.5B	118.2%
2026 Q1	559	57.1M	$9.6B	117.9%
2025 Q4	586	52.9M	$10.5B	109.1%
2025 Q3	554	50.4M	$7.9B	104.0%
2025 Q2	521	50.9M	$7.7B	105.0%
2025 Q1	567	53.4M	$8.0B	110.2%
2024 Q4	640	53.1M	$9.7B	109.4%
2024 Q3	630	52.1M	$10.1B	107.5%
2024 Q2	665	52.4M	$10.6B	108.1%
2024 Q1	678	52.3M	$13.7B	107.8%
2023 Q4	638	52.1M	$11.9B	107.4%
2023 Q3	623	51.8M	$9.8B	106.9%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Parisotto Shannon M	CEVP, Disc & Safety Assessment	2026-10-05	EXERCISE	981	$0.20M	5,788
Parisotto Shannon M	CEVP, Disc & Safety Assessment	2026-10-05	SELL	981	$0.30M	4,807
Parisotto Shannon M	CEVP, Disc & Safety Assessment	2026-10-05	EXERCISE	981	$0.20M	2,944
Coleman Glenn	EVP & Chief Financial Officer	2026-09-30	BUY	10	$0.00M	27,762
Foster James C	director	2026-08-25	EXERCISE	21,132	$4.10M	52,728
Foster James C	director	2026-08-25	EXERCISE	12,429	$2.59M	65,157
Foster James C	director	2026-08-25	SELL	33,561	$10.07M	31,596
Foster James C	director	2026-08-25	EXERCISE	21,132	$4.10M	7,044

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	19	166,971	$42.9M	Counted
P — Open-market purchases	2	35	$0.0M	Counted
M — Exercises (paired A/D)	12	82,625	$15.6M	None — mechanics
F — Tax withholding	25	8,120	$1.4M	None — compensation
G — Gifts	6	192,240	—	None

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalTwo-Way Flow

Open-Market Sells$42.9M19 txns / 6 mo

Open-Market Buys$0.0M2 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-10-05	Parisotto Shannon M	981	$0.3M
2026-08-19	Parisotto Shannon M	2,039	$0.6M
2026-08-18	Nancy C Andrews	573	$0.2M
2026-08-11	Parisotto Shannon M	3,714	$1.0M
Trailing 12 mo	10 filings	133,410	$33M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2026-09-08	SCHEDULE 13G/A	Abigail P. Johnson	10.20%	4.9M sh
2026-08-13	SCHEDULE 13G	Invesco Ltd.	6.20%	3.0M sh
2026-08-06	SCHEDULE 13G/A	Abigail P. Johnson	8.80%	4.2M sh
2026-05-06	SCHEDULE 13G	Abigail P. Johnson	7.00%	3.5M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Rob Bresnahan	House	SELL	$1,001 - $15,000	2025-05-15	2025-06-02
Robert P. Bresnahan	House	SELL	$1,001 - $15,000	2025-05-14	2025-06-02
Jefferson Shreve	House	SELL	$15,001 - $50,000	2025-05-12	2025-06-23

House 12-Mo0 tradesNone purchases

Senate 12-Mo0 tradesNone purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)559

13F Shares57M117.9% of shares out

New / Closed72 / 87positions, QoQ

Increased / Reduced192 / 199positions, QoQ

Put/Call (13F)1.22option positions

Free Float98.0%47M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	198,728	$59M
Confluence Investment Management L	82,373	$24M
Td Waterhouse Canada Inc.	31,135	$9M
Sendero Wealth Management, Llc	20,125	$6M
Czech National Bank	13,717	$4M
Atria Investments, Inc	5,955	$2M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
FCNKX	0.3%	$526M
FCNTX	0.3%	$526M
VITSX	0.0%	$447M
VTI	0.0%	$447M
VSMPX	0.0%	$447M
VTSAX	0.0%	$447M

13F Filers Holding CRL — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session63.1%2026-10-15

20-Day Avg61.0%50-day 50.5%

TrendRising20d vs 50d

By Market CenterQ: 64% · N: 59% · B: 43%latest session

Weekly Notional ($B)

Where CRL Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	1.3M	46 sh
Sgmt Sigma X2	1.0M	31 sh
Mlix Instinct X	0.8M	49 sh
Ebxl Level Ats	0.7M	25 sh
Bids Bids Ats	0.6M	691 sh
Mstx Ms Trajectory Cross (Ats-1)	0.5M	26 sh

Where a dollar of Charles River Laboratories International, Inc. revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$2.1B	54%
Europe	$1.1B	28%
CANADA	$501M	13%
Asia Pacific	$205M	5%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

CRL (live moat model)Peer median: ICLR · RVTY · MEDP · EXAS · GH

Component scores from the live moat model. Peer median illustrative.

Moat score 41/100 — Weak; primary source Efficient Scale.

3.8 · Employees (SEC filings)

Officer	Title
Birgit Girshick	CEO & Director
Joseph W. LaPlume	Corporate Executive Vice President of Corporate Development & Strategy
Victoria L. Creamer	Corporate Executive Vice President & Chief People Officer
Glenn G. Coleman	Corporate Executive Vice President & Chief Financial Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)6 of 6recent quarters

Avg Surprise+10.2%

Next Report2026-11-04

Income QualityN/Mloss-making — OCF ÷ net income not meaningful

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+21.1%	+12.3%	+3.9%	-1.9%	-0.9%
Gross profit	+24.3%	+9.6%	+2.7%	-11.4%	-8.0%
Operating income	+36.3%	+10.4%	-5.2%	-63.2%	+123.4%
Net income	+7.3%	+24.4%	-2.4%	-97.8%	-1501.7%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	3.5	4.0	4.1	4.0	4.0
Cost of revenue	2.2	2.5	2.6	2.7	2.8
Gross profit	1.3	1.5	1.5	1.3	1.2
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	0.6	0.7	0.7	0.8	0.7
Operating income	0.6	0.7	0.6	0.2	0.5
EBITDA	0.8	1.0	1.0	0.6	0.9
D&A	0.3	0.3	0.3	0.4	0.4
Pretax income	0.5	0.6	0.6	0.1	-0.1
Income tax	0.1	0.1	0.1	0.1	0.0
Net income	0.4	0.5	0.5	0.0	-0.1
Diluted EPS ($)	7.60	9.48	9.22	0.20	-2.91
Diluted shares (M)	51	51	51	52	50

Operating CF$1B

CapEx$0B

Free cash flow$1B

SBC$0B

Buybacks$0B

Net cash change$0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.2	0.3	0.2	0.2
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	0.8	0.8	0.7	0.7
Total current assets	1.4	1.6	1.4	1.4
PP&E (net)	1.9	2.0	2.0	2.0
Goodwill + intangibles	3.8	4.0	3.6	3.1
Total assets	7.6	8.2	7.5	7.1
Accounts payable	0.2	0.2	0.1	0.1
Short-term debt	0.0	0.0	0.0	0.1
Deferred revenue	0.3	0.2	0.2	0.2
Total current liabilities	1.1	1.1	1.0	1.1
Long-term debt	2.7	2.6	2.2	2.5
Total liabilities	4.6	4.5	4.0	3.9
Shareholders' equity	3.0	3.7	3.5	3.2

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.5	0.5	0.0	(0.1)
D&A	0.3	0.3	0.4	0.4
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	(0.2)	(0.1)	(0.0)	0.0
Operating cash flow	0.6	0.7	0.7	0.7
Capital expenditures	(0.3)	(0.3)	(0.2)	(0.2)
Investing cash flow	(0.6)	(0.6)	(0.2)	(0.2)
Buybacks	(0.0)	(0.0)	(0.1)	(0.4)
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	0.0	(0.1)	(0.4)	(0.1)
Financing cash flow	(0.0)	(0.1)	(0.6)	(0.5)
Free cash flow	0.3	0.4	0.5	0.5

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	16.8%	17.6%	14.4%	0.3%	-4.4%	-8%
ROA	6.2%	6.6%	6.0%	0.1%	-2.0%	-3.2%
ROIC	8.9%	8.8%	8.0%	1.0%	5.6%	7.7%
Gross margin	37.7%	36.8%	36.4%	32.9%	30.5%	32.2%
Operating margin	16.7%	16.4%	14.9%	5.6%	12.6%	12.3%
Net margin	11.0%	12.2%	11.5%	0.3%	-3.6%	-6.0%
EBITDA margin	23.2%	24.8%	25.0%	14.3%	22.7%	5.5%
FCF margin	15.0%	7.4%	8.8%	12.4%	12.9%	—
VALUATION
P/E	49.68	23.02	25.71	916.78	-69.44	-62.0
P/B	7.66	3.76	3.39	2.73	3.17	5.1
P/S	5.49	2.82	2.96	2.33	2.50	3.62
P/FCF	36.51	37.96	33.40	18.82	19.33	39.0
EV/EBITDA	27.29	14.26	14.53	20.60	31.34	78.4
EV/Revenue	6.32	3.54	3.63	2.96	3.21	4.3
Earnings yield	2.0%	4.3%	3.9%	0.1%	-1.4%	-1.64%
FCF yield	2.7%	2.6%	3.0%	5.3%	5.2%	2.56%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.23	1.32	1.52	1.41	1.29	1.35
Quick ratio	1.04	1.08	1.16	1.13	1.02	1.04
Debt / equity	1.26	1.04	0.85	0.79	0.97	1.07
Debt / assets	45.6%	40.7%	37.4%	36.2%	43.0%	40.2%
Net debt / EBITDA	3.61	2.90	2.70	4.35	6.94	12.86
Interest coverage	7.50	11.51	5.25	1.74	0.07	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.57	0.54	0.52	0.52	0.55	0.53
Receivables turnover	5.62	6.68	7.50	7.63	6.59	5.6
DSO (days)	65	55	49	48	55	65
DPO (days)	27	29	26	21	20	19
Cash conversion cycle	70	58	67	71	75	93
GROWTH (YoY)
Revenue growth	21.1%	12.3%	3.9%	-1.9%	-0.9%	—
Net income growth	7.3%	24.4%	-2.4%	-97.8%	-1501.7%	—
EPS growth	6.2%	24.8%	-2.9%	-97.8%	-1556.5%	—
FCF growth	40.0%	-44.6%	23.9%	37.3%	3.4%	—
PER SHARE ($)
EPS (diluted, TTM)	7.58	9.46	9.19	0.20	-2.93	-4.92
Book value / share	49.17	57.93	69.67	67.69	64.30	58.70
Revenue / share	68.67	77.39	79.99	79.20	81.59	82.48
FCF / share	10.32	5.74	7.08	9.81	10.54	7.64
Cash / share	4.78	4.55	5.36	3.81	4.34	3.96
SHAREHOLDER RETURN & SCORES
Buyback yield	0.2%	0.3%	0.2%	1.3%	3.6%	3.10%
Altman Z-Score	3.63	2.60	2.81	2.45	2.43	2.7
Piotroski F-Score	5	8	5	6	5	5/9
Beneish M-Score	-2.55	-2.40	-2.55	-2.90	-3.15	-3.11

Model	Score	Zone	Note
Piotroski F-Score	5 / 9	Middling
Altman Z-Score	2.7	Grey zone	Grey
Income quality	N/M	Loss-making	OCF ÷ net income not meaningful with negative earnings; OCF itself is the signal
Beneish M-Score	-3.11	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	1.30
Interest burden	2.37
Operating margin	-1.9%
Asset turnover	0.53×
Financial leverage	2.44×
= ROE	-8%

Growth Quality (live)	Value
Revenue stability	0.48
Earnings stability	0.67
Earnings persistence	0.50
Revenue CAGR 3y	-1.5%
EPS CAGR 3y	—
FCF CAGR 3y	8.6%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield3.10%

Dividend Yield0.00%none paid

Total Shareholder Return3.08%cash yield

SBC / Revenue1.6%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
ICLR	$13.1B	39.7	3%	3.5%	+2.0%	6/9	-9.7%
RVTY	$17.0B	72.7	3%	7.1%	+5.5%	6/9	+62.5%
MEDP	$17.3B	35.6	162%	17.2%	+24.7%	8/9	+18.7%
EXAS	$20.0B	-188.6	-9%	-9.8%	+17.7%	7/9	+119.7%
GH	$21.3B	-45.4	172%	-35.9%	+42.7%	6/9	—
QGEN	$9.5B	23.7	12%	19.3%	+3.0%	8/9	—
LH	$25.8B	26.1	12%	8.0%	+6.4%	8/9	—
DGX	$25.9B	24.6	14%	10.5%	+9.9%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

37 Analysts

Str Sell (0)Sell (0)Hold (10)Buy (26)Str Buy (1)

Mean Target (qtr)$315.0017 targets

Target vs. Price+4.9%last-quarter mean

Next Report2026-11-04street $2.97

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$3.92B	$3.98B / $3.91B	$11.38	$11.50 / $11.19	10
FY2026	$4.08B	$4.09B / $4.06B	$11.00	$11.33 / $10.19	10
FY2027	$4.01B	$4.09B / $3.95B	$12.80	$13.05 / $12.09	10

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$329.78	+9.9%	9
Last Quarter	$315.00	+4.9%	17
Last Year	$258.80	-13.8%	40
All Time	$268.77	-10.5%	62

Rolling mean of published targets vs. last close $300.15. Aggregated from StreetInsider, Pulse 2.0, Benzinga.

Third-Party Composite Rating

C-

DCF

3/5

ROE

1/5

ROA

1/5

Debt/Eq

1/5

P/E

1/5

P/B

2/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

CRL +71.6% vs S&P 500 +15.9% — spread +55.8pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$295.83	+4.32	+1.46%	Above
SMA 50	$288.88	+11.27	+3.90%	Above
SMA 200	$215.10	+85.05	+39.54%	Above
EMA 9	$300.70	-0.55	-0.18%	Below
EMA 21	$295.87	+4.28	+1.45%	Above
EMA 50	$281.89	+18.26	+6.48%	Above
EMA 200	$229.29	+70.86	+30.90%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTBULLISHPower Score +4217 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%90

Momentum 25%60

Volume 20%75

Volatility 10%83

Patterns 15%38

This Week82% bullishof 11 price-based votes

4 Weeks Ago27%+55 pts since

12 Weeks Ago91%-9 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$295.83

Price vs SMA 50$288.88

Price vs SMA 200$215.10

EMA 9/21 Cross300.7/295.9

SMA 50/200Golden

ADX DirectionADX 34

Supertrend$278

Parabolic SAR$328

SMA Slope1.110

RSI55.7

Stochastic K/D37/39

StochRSI K/D38/39

Williams %R-68

CCI65

TSI vs Signal16.7

CMO11.3

ROC3.47%

OBV SignalDistrib

Chaikin MF0.100

MFI62

Force Index0M

Elder Ray Bull13.53

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 39

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$303.71 / $312.01 / $317.79	S1 / S2	$297.93 / $289.63
Bollinger (20,2)	$278.82 – $312.83	Squeeze	ON
52-wk range	$146.20 – $333.30	Off 52-wk high	-9.9%
ATR (14)	$11.56 (3.9%)	Historical vol	40.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+2.6%Jan65%

+0.7%Feb55%

+0.0%Mar71%

-3.1%Apr45%

+2.7%May70%

+2.1%Jun55%

+4.1%Jul65%

-0.9%Aug40%

+0.3%Sep55%

-1.3%Oct55%

-0.5%Nov55%

+3.2%Dec70%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	CRL	S&P 500
Weekly volatility (σ, 1y)	7.09%	1.83%
Best / worst week (1y)	+21.5% / -17.7%	—
Max drawdown (5y, monthly)	-73.5%	—
1-week VaR (95%)	-15.4%	—
Beta (5y)	1.41	1.00

CRL EQUITY WEATHER (LIVE)CLOUDY · +14

Trend+43

Momentum+7

Volume+32

Volatility-30

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 124 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall+13.8+30.8 vs industry

Trend+43.4+50.6 vs industry

Momentum+7.4+34.4 vs industry

Volume+32.2+32.2 vs industry

Reading	CRL	Medical - Diagnostics & Research n=227	Healthcare n=5,272	All US symbols n=70,435
Overall	+13.8	-17.0	-24.0	-20.5
Trend	+43.4	-7.2	-25.6	-21.3
Momentum	+7.4	-27.0	-28.5	-15.8
Volume	+32.2	+0.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
James C. Foster Chair, President, Chief Exec	$14.1M	73% equity+incentive
Birgit Girshick Corporate Executive Vice Pre	$5.0M	68% equity+incentive
Flavia H. Pease Corporate Executive Vice Pre	$3.8M	54% equity+incentive
Joseph LaPlume Corporate Executive Vice Pres	$3.1M	65% equity+incentive
William D. Barbo Corporate Executive Vice Pr	$2.9M	64% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	65
Social	72
Governance	72
Composite ESG	70

Composite ESG Trend

Filed	8-K contents	Items
2026-09-24	Regulation FD; Exhibits	7.01,9.01
2026-08-05	Earnings Release; Exhibits	2.02,9.01
2026-05-07	Earnings Release; Exhibits	2.02,9.01
2026-02-25	Regulation FD Disclosure	7.01
2026-02-18	Departure/Election of Directors; Appointment of Officers; Financial St	5.02,9.01
2026-02-18	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2026-01-13	Results of Operations and Financial Condition; Regulation FD Disclosur	2.02,7.01
2026-01-09	Departure/Election of Directors; Appointment of Officers	5.02

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-08-05
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-27 to 2027-12-27
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	105 rows · 2000 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-08-19 to 2026-10-05
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-05-06 to 2026-09-08
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

Charles River Laboratories International, Inc. (CRL)

Institutions holding — 12 quarters

Charles River Laboratories International, Inc. (CRL)

Monthly Net Insider Flow (000 shares)

Signal Summary

Charles River Laboratories International, Inc. (CRL)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding CRL — quarterly

Institutional Put/Call — quarterly

Charles River Laboratories International, Inc. (CRL)

Where CRL Trades in the Dark

Charles River Laboratories International, Inc. (CRL)

3.8 · Employees (SEC filings)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Balance Sheet — Full

Cash Flow Statement — Full

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Street Price Target — Trajectory

Third-Party Composite Rating

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Family Scores (site weights)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)

Charles River Laboratories International, Inc. (CRL)